CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PharmNovo is developing a novel drug, PN6047, for treating chronic pain, particularly neuropathic pain. This drug selectively targets specific receptors to minimize side effects associated with traditional opioids, aiming for safer pain management solutions.
PharmNovo aims to develop novel drugs with superior clinical properties to treat patients suffering from chronic pain using knowledge and experience in drug design and G protein-coupled receptor pharmacology.Pharmnovos lead drug candidate is PN6047 - a completely new type of opioid drug for neuropathic pain, with a first-in-class market potential.
Unlike the currently available opioid drugs which activate all opioid receptors, PN6047 is a very selective delta opioid receptor agonist (activator).…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
